Recro Pharma (NASDAQ:REPH) Rating Lowered to Hold at ValuEngine

Recro Pharma (NASDAQ:REPH) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Tuesday, ValuEngine reports.

Other equities analysts have also recently issued reports about the stock. Stephens dropped their price objective on shares of Recro Pharma from $23.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Wednesday, October 30th. Oppenheimer set a $20.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a report on Friday, August 9th. Finally, BidaskClub upgraded shares of Recro Pharma from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $14.90.

REPH opened at $16.57 on Tuesday. Recro Pharma has a 52 week low of $5.53 and a 52 week high of $18.20. The business has a 50 day moving average price of $15.22 and a two-hundred day moving average price of $11.69. The company has a market cap of $376.41 million, a PE ratio of -6.65 and a beta of -0.35.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.06). The firm had revenue of $25.26 million during the quarter, compared to analyst estimates of $19.83 million. Analysts predict that Recro Pharma will post -0.71 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its holdings in shares of Recro Pharma by 635.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,943 shares of the specialty pharmaceutical company’s stock valued at $33,000 after buying an additional 2,543 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Recro Pharma in the second quarter worth $48,000. Metropolitan Life Insurance Co NY purchased a new stake in shares of Recro Pharma in the third quarter valued at $84,000. Paloma Partners Management Co purchased a new stake in shares of Recro Pharma in the second quarter valued at $109,000. Finally, Meeder Asset Management Inc. boosted its stake in shares of Recro Pharma by 153.5% during the second quarter. Meeder Asset Management Inc. now owns 12,895 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 7,809 shares during the last quarter. 58.69% of the stock is owned by institutional investors and hedge funds.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Article: Technical Indicators – What is a Golden Cross?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.